IRD insider transactions
Opus Genetics Inc. (IRD) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
IRD insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Opus Genetics Inc., latest first. Follow anyone to get their next filing.
- George MagrathChief Executive Officer, Director, since November 2023+$257K-$315K
- Foundation Fighting Blindness Retinal Degeneration FundDirector, since October 2024-$18.8M
- Cam GallagherDirector+$324K
- Robert E. GagnonChief Financial Officer, since September 2025-$191K
- Benjamin R YerxaPresident, Director, since October 2024+$9,834-$61.2K
- Joseph K SchachleChief Operating Officer, since November 2023+$4,100-$57.7K
- Rabourn Amy ZarembaHead of Fin. Quality Assurance-$23.3K
- Ashwath JayagopalChief Scientific & Dev. Ofc., since February 2024+$6,178-$58.2K
- Richard J RodgersDirector
- Manuso James S JDirector+$17K
- Susan BentonDirector+$91.4K
- Adrienne L GravesDirector, since October 2024
- Jean BennettDirector, since October 2024
- Sean AinsworthDirector
- Nirav S. JhaveriChief Financial Officer, since February 2024+$21K
- Bernhard HoffmannSVP of Corp. Dev.
- Jay PeposeDirector, since June 2021+$90.1K
- Ronil A. PatelChief Business Officer, since April 2023
- Mina SoochOfficer, Director+$51.2K
Recent Form 3, 4, and 5 filings for IRD
- Chief Executive Officer Magrath George sold $110,184 worth of shares (28,258 units at $3.90), decreasing direct ownership by 1% to 2,010,636 units (SEC Form 4) to satisfy withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K sold $16,994 worth of shares (4,767 units at $3.57) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R sold $117,365 worth of shares (33,189 units at $3.54) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. sold $49,650 worth of shares (14,000 units at $3.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George sold $34,384 worth of shares (9,591 units at $3.59) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $2,755,981 worth of shares (556,000 units at $4.96) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George exercised 392,157 shares at a strike of $1.15 and covered exercise/tax liability with 75,541 shares, increasing direct ownership by 18% to 2,048,485 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. sold $127,212 worth of shares (28,000 units at $4.54) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 556,375 units (SEC Form 4) to cover withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam exercised 784,314 shares at a strike of $1.15, increasing direct ownership by 39% to 2,800,111 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R sold $22,064 worth of shares (7,429 units at $2.97), decreasing direct ownership by 1% to 704,106 units (SEC Form 4) to satisfy withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K sold $13,653 worth of shares (4,644 units at $2.94), decreasing direct ownership by 2% to 291,440 units (SEC Form 4) (withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George sold $27,926 worth of shares (9,475 units at $2.95), decreasing direct ownership by 0.54% to 1,731,869 units (SEC Form 4) to satisfy tax liability4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. sold $22,942 worth of shares (7,783 units at $2.95), decreasing direct ownership by 1% to 584,375 units (SEC Form 4) to cover taxes4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $7,395,000 worth of shares (1,700,000 units at $4.35) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K sold $24,519 worth of shares (4,697 units at $5.22), decreasing direct ownership by 2% to 296,084 units (SEC Form 4) (withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R sold $39,121 worth of shares (7,470 units at $5.24), decreasing direct ownership by 1% to 711,535 units (SEC Form 4) to satisfy withholding obligation4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy sold $8,540 worth of shares (1,641 units at $5.20), decreasing direct ownership by 0.86% to 188,671 units (SEC Form 4) (for withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George sold $49,647 worth of shares (9,511 units at $5.22), decreasing direct ownership by 0.54% to 1,741,344 units (SEC Form 4) (withholding obligation)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath sold $39,156 worth of shares (7,542 units at $5.19), decreasing direct ownership by 1% to 509,233 units (SEC Form 4) to cover taxes4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. sold $40,658 worth of shares (7,842 units at $5.18), decreasing direct ownership by 1% to 592,158 units (SEC Form 4) (withholding obligation)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Rodgers Richard J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Manuso James S J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Benton Susan4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Gallagher Cam4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Graves Adrienne L4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Bennett Jean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Ainsworth Sean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Schachle Joseph K4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Zaremba Rabourn Amy4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Magrath George4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Jayagopal Ashwath4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath covered exercise/tax liability with 5,313 shares, decreasing direct ownership by 1% to 520,494 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R was granted 400,000 shares, increasing direct ownership by 125% to 719,005 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K was granted 250,000 shares, increasing direct ownership by 459% to 304,500 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy was granted 86,500 shares, increasing direct ownership by 81% to 193,128 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George was granted 483,639 shares, increasing direct ownership by 37% to 1,775,293 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath was granted 400,000 shares, increasing direct ownership by 318% to 525,807 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. was granted 400,000 shares, increasing direct ownership by 200% to 600,000 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,390 shares, decreasing direct ownership by 3% to 106,628 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,950 shares, decreasing direct ownership by 3% to 110,018 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 67,000 shares, increasing direct ownership by 3% to 1,991,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Manuso James S J was granted 31,188 shares, increasing direct ownership by 12% to 292,951 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Graves Adrienne L was granted 23,643 shares, increasing direct ownership by 30% to 103,147 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Bennett Jean was granted 21,127 shares, increasing direct ownership by 10% to 234,652 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Ainsworth Sean was granted 42,507 shares, increasing direct ownership by 17% to 297,325 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $8,600,000 worth of shares (4,000,000 units at $2.15) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Amendment: Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)4/A - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R covered exercise/tax liability with 23,795 shares, decreasing direct ownership by 7% to 319,005 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. was granted 200,000 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 3 filed by new insider Gagnon Robert E.3 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 869,565 shares, increasing direct ownership by 92% to 1,810,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Ainsworth Sean was granted 86,956 shares, increasing direct ownership by 52% to 254,818 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund converted options into 6,927,419 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Rodgers Richard J was granted 79,504 shares, increasing direct ownership by 33% to 318,655 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Manuso James S J was granted 79,504 shares, increasing direct ownership by 44% to 261,763 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Graves Adrienne L was granted 79,504 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 79,504 shares, increasing direct ownership by 9% to 940,865 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Benton Susan was granted 79,504 shares, increasing direct ownership by 57% to 219,527 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)